Status:
COMPLETED
Natrecor for Pulmonary Hypertension in Lung Transplants
Lead Sponsor:
University of Wisconsin, Madison
Conditions:
Pulmonary Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This study seeks to demonstrate that Natrecor® (nesiritide) is safe and effective and has a favorable hemodynamic profile in lung transplant recipients that will allow for the avoidance of inhaled nit...
Detailed Description
A condition called ischemic reperfusion injury (IRI) occurs in all lung transplants. The amount of reperfusion injury varies from person to person. IRI occurs when the blood supply to tissue (in this ...
Eligibility Criteria
Inclusion
- Single or double lung transplant or heart/lung transplant recipient
- Planned use of Natrecor
- Pulmonary artery (PA) systolic pressures \> 35
Exclusion
- Previous lung transplant
- Use of Prolastin after pneumonectomy
- Mean arterial pressure of \< 55
- Known allergy or sensitivity to nesiritide
- Females of childbearing potential with a positive pregnancy test or women who are breast feeding
- Use of nesiritide, for any reason, within 30 days prior to transplant
Key Trial Info
Start Date :
August 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2006
Estimated Enrollment :
7 Patients enrolled
Trial Details
Trial ID
NCT00205426
Start Date
August 1 2005
End Date
May 1 2006
Last Update
October 14 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Wisconsin Hospital and Clinics
Madison, Wisconsin, United States, 53792